Trial of redirected HBV-targeting T cells for liver cancer
Part of Cancer, Digestive system, Infections clinical trials.
This Phase 1 study tests a lab-made immune cell treatment that targets hepatitis B (HBV)–related liver cancer. It may help by directing the body’s immune system to attack the cancer, while carefully checking safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (hepatocellular carcinoma) in the liver that can be measured and can’t be treated with standard options or those options already didn’t work
- Your hepatitis B test shows HBsAg positive
- Your liver scarring is not severe: you have no cirrhosis, or “compensated” cirrhosis (Child-Pugh A only)
- Your general health is fairly good (ECOG 0 to 1) and you have at least 3 months of expected survival
- Your blood type markers fit the needed T-cell targeting pattern (HLA class 1 matching, specifically HLA-A*02:01 or HLA-A*24:02)
- You cannot have certain recent treatments, medicines, or infections that could interfere with the study or make side effects more likely
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (LioCyx-M) for people with advanced liver cancer caused by hepatitis B. It uses specially designed T cells (a type of immune cell) that target the hepatitis B virus and may help fight the cancer.
This trial tests a special type of immune cell therapy (called HBV-TCR T cells) that is designed to attack liver cancer cells that carry the hepatitis B virus. It may be given alone or combined with a pill called lenvatinib to see if it can shrink tumors and help people with advanced liver cancer.
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This trial tests a new combination for liver cancer that cannot be surgically removed yet. It uses tiny radioactive beads (yttrium-90) to deliver radiation directly to the tumor, along with immunotherapy drugs and a targeted therapy to shrink the tumor, with the hope that it can later be surgically removed.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.